These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21885210)

  • 1. Major depression and treatment response in adolescents with ADHD and substance use disorder.
    Warden D; Riggs PD; Min SJ; Mikulich-Gilbertson SK; Tamm L; Trello-Rishel K; Winhusen T
    Drug Alcohol Depend; 2012 Jan; 120(1-3):214-9. PubMed ID: 21885210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
    Tamm L; Trello-Rishel K; Riggs P; Nakonezny PA; Acosta M; Bailey G; Winhusen T
    J Subst Abuse Treat; 2013 Feb; 44(2):224-30. PubMed ID: 22889694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
    Winhusen TM; Lewis DF; Riggs PD; Davies RD; Adler LA; Sonne S; Somoza EC
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):455-63. PubMed ID: 22040190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders.
    Gray KM; Riggs PD; Min SJ; Mikulich-Gilbertson SK; Bandyopadhyay D; Winhusen T
    Drug Alcohol Depend; 2011 Sep; 117(2-3):242-7. PubMed ID: 21411243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.
    Nunes EV; Covey LS; Brigham G; Hu MC; Levin FR; Somoza EC; Winhusen TM
    J Clin Psychiatry; 2013 Oct; 74(10):983-90. PubMed ID: 24229749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
    Konstenius M; Jayaram-Lindström N; Guterstam J; Beck O; Philips B; Franck J
    Addiction; 2014 Mar; 109(3):440-9. PubMed ID: 24118269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD.
    Luo SX; Covey LS; Hu MC; Winhusen TM; Nunes EV
    Am J Addict; 2019 Nov; 28(6):497-502. PubMed ID: 31538372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.
    Luo SX; Wall M; Covey L; Hu MC; Scodes JM; Levin FR; Nunes EV; Winhusen T
    Am J Drug Alcohol Abuse; 2018; 44(6):653-659. PubMed ID: 29370538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.